Stem Cell Advisor

By Dr. Frank Yap, MD · OneDayMD Network · Last reviewed and updated: November 15, 2026 · Originally published June 2022 Quick answer No stem cell clinic is “FDA-approved.” The FDA licenses products, not clinics, and the only stem-cell-based products it has approved are for specific blood and immune conditions: cord blood products, Omisirge, and, since December 2024, Ryoncil, the first mesenchymal stromal cell therapy (for pediatric steroid-refractory acute graft-versus-host disease). The providers below mostly market other uses (joint pain, multiple sclerosis, heart failure, autoimmune disease, “anti-aging”) for which no stem cell product is approved. We profile them so readers can research them, not as recommendations . For most, the best public evidence we could find is uncontrolled (CEBM Level 4–5). This guide profiles eight stem cel...

Last updated October 2026 · Originally published November 2022 At first, the trend was subtle. But, the tide has swelled and created a craze for promising CAR-T product candidates. Driven by approvals of the CAR-T products Kymriah and Yescarta, there has been a rush to chase the next CAR-T success. CAR T-cell therapy (Chimeric Antigen Receptor T-Cell) is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.” The global CAR t-cell therapy market size was valued at USD 5.8 billion in 2025 and is projected to grow from USD 6.9 billion in 2026 to USD 22.3 billion by 2033, at a CAGR of 18.1% from 2026 to 2033. The market in North America dominated with a revenue share of 61.1% in 2025. Market growth is driven by rising cancer prevalence, adoption of personalized c...